focus on

Wuliangye was rated by Essence Securities with a buy rating. Recently, it has been concerned by 3 brokerage research reports. The average price rose by 28.63%.

AnxinsecuritiesPosted on April 24thResearch reportsay, giveWuliangye(000858.SZ, latest price: 165.43 yuan) Buy rating, target price of 222 yuan. The reasons for the rating mainly include: 1)WuliangyeDilemma: making money vs. diversion; 2) Analysis of the reasons: cost-driven price increases are subject to external conditions, and the channel model needs to be improved; 3) Operational reform: born in … Read more

Strategy Comments: The central bank’s comprehensive RRR cuts focus on the direction of “steady growth”_Oriental Fortune Network

event On April 15, the Chinese peoplebankDecision to downgrade financial institutions on April 25, 2022deposit reserverate 0.25 percentage points (excluding 5% that have been implementeddeposit reserve ratiofinancial institutions). In order to increase support for small and micro enterprises and “agriculture, rural areas and farmers”, for urban commercial banks that do not operate across provinces and … Read more

[Funding route map on the 28th]Northbound funds flow back!Net purchases of more than 5 billion yuan throughout the day, the main funds focus on the weighted sectors such as finance and real estate_Oriental Fortune Net

On March 28, the A-share market rose as a whole. As of the close,The Shanghai Composite IndexIt closed at 3214.5 points, up 0.07%;Shenzhen Component IndexIt closed at 11949.94 points, down 1.02%;GEM refers toIt closed at 2594.13 points, down 1.66%. The total turnover of the two cities was 870.386 billion yuan, a decrease of 47.876 billion … Read more

Chemical and pharmaceutical: 5 Chinese companies have been authorized by Pfizer’s new crown drug MPP to pay attention to investment opportunities in related industry chains – yqqlm

Event: On March 17th, the Geneva Medicines Patent Pool (MPP) announced that it signed an agreement with 35 companies around the world to authorize productionPfizerOral new crown treatment drug nirmatrelvir (PF-07321332) API or/and preparation. Authorized generic companies will be able to deliver the Paxlovid combination therapy to 95 low- and middle-income countries around the world, … Read more